18550-98-6
3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
CAS: 18550-98-6
Molecular Formula: C13H10N2O
18550-98-6 - Names and Identifiers
18550-98-6 - Physico-chemical Properties
| Molecular Formula | C13H10N2O |
| Molar Mass | 210.23 |
| Density | 1.192±0.06 g/cm3(Predicted) |
| Boling Point | 387.8±42.0 °C(Predicted) |
| Solubility | DMSO : 30 mg/mL mother liquor preservation: sub-package and freeze storage to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 months (after dilution, the solution temperature is low and storage may precipitate, try to use it now) Cell experiment: Dissolve with DMSO first: dilute with culture medium then, and the dilution process is recommended to be carried out in stages to avoid too fast concentration change leading to compound precipitation. If the compound is precipitated during the dilution process, it can be redissolved by ultrasound. During dilution, ensure that the final concentration of DMSO in the working fluid should be below 0.1% as far as possible, and the maximum should not exceed 0.5%, and set up a DMSO control group with corresponding concentration. Animal experiment: Dissolve with DMSO first: dilute with water or normal saline, etc. The dilution process is recommended to be carried out in sections to avoid excessive concentration changes leading to compound p |
| Appearance | powder |
| Color | white to beige |
| pKa | 3.49±0.11(Predicted) |
| Storage Condition | 2-8°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| Use | 3PO is a PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor. 3PO reduces glycolytic flux and suppresses glucose uptake. 3PO may be useful agents in combination with other drugs that inhibit cancer cell proliferation. PFKFB3 inhibitors suppress glucose uptake, which in turn causes an increase in autophagy. The addition of selective inhibitors of autophagy to 3PO and its more potent derivatives may prove useful as rational combinations for the treatment of cancer. Note: this product has been assigned 2 CAS#: 18550-98-6 and 13309-08-5, |
| In vitro study | 3PO inhibits PFKFB3, but not purified PFK-1 activity, primarily by competing with Fru-6-P. In a variety of human-derived hematological malignancies and cancer cell lines, 3PO significantly slowed their cell proliferation (IC50=1.4-24 μm). 3PO selectively inhibits the growth of airway epithelial cells transfected with ras compared to normal human airway epithelial cells. 3PO can cause cell cycle G2-M phase arrest. |
| In vivo study | Tumor-bearing mice were injected intraperitoneally with 0.07 mg of 3PO. Administration of 3PO significantly reduced intracellular Fru-2,6-BP concentration, glucose uptake, and tumor growth. It inhibits tumor growth of breast cancer, leukemia and lung cancer cells. 3PO was injected intravenously into C57Bl/6 mice to detect its pharmacokinetic parameters in vivo: CL = 2312 mL/min/kg, T 1/2=0.3 hr, max C = 113 ng/ml, auc0-inf = 36 ng/hr/ml. In a highly relevant mouse model of leukemia, 3PO has potent antitumor activity. |
18550-98-6 - Reference
| Reference Show more | 1: Lea MA, Guzman Y, Desbordes C. Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3. Anticancer Res. 2016 Apr;36(4):1479-88. PubMed PMID: 27069123. 2: Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, Gallagher L, Smith T, Phelan JJ, Ryan J, O'Sullivan J, Ng CT, Veale DJ, Fearon U. Dysregulated bioenergetics: a key regulator of joint inflammation. Ann Rheum Dis. 2016 Mar 24. pii: annrheumdis-2015-208476. doi: 10.1136/annrheumdis-2015-208476. [Epub ahead of print] PubMed PMID: 27013493. 3: Saneei A, Pourayoubi M, Crochet A, Fromm KM. The first phosphoramide-mercury(II) complex with a Cl2Hg-OP[N(C)(C)]3 segment. Acta Crystallogr C Struct Chem. 2016 Mar 1;72(Pt 3):230-3. doi: 10.1107/S2053229616002394. Epub 2016 Feb 25. PubMed PMID: 26942433. 4: Nakajima J, Suganami Y, Tsutsumi N, Hirose A, Kondo A, Sunohara D, Kawashima H. Legal Problems Surrounding Medical Care for Neonates Born to International Students: Report of Two Families in Japan. J Immigr Minor Health. 2016 Feb 24. [Epub ahead of print] PubMed PMID: 26911876. 5: Lea MA, Altayyar M, desBordes C. Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism. Anticancer Res. 2015 Nov;35(11):5889-99. PubMed PMID: 26504012. 6: Maeda M, Kayano E, Fujiwara T, Nagare H, Akao S. Nitrous oxide emission |
18550-98-6 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 4.757 ml | 23.783 ml | 47.567 ml |
| 5 mM | 0.951 ml | 4.757 ml | 9.513 ml |
| 10 mM | 0.476 ml | 2.378 ml | 4.757 ml |
| 5 mM | 0.095 ml | 0.476 ml | 0.951 ml |
Last Update：2024-01-02 23:10:35
18550-98-6 - Reference Information
| biological activity | 3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-proben-1-one) it is a small molecule inhibitor of PFKFB3, and has an IC50 of 22.9 μm for human recombinant PFKFB3 protein, and does not inhibit the activity by PFK-1. It is capable of inhibiting glucose uptake, reducing intracellular concentrations of Fru-2,6-BP, lactate, ATP, NAD and NADH. |
| Target | Value |
| PFKFB3 () | 22.9 μM |
Last Update：2024-04-09 21:04:16
Supplier List
Spot supply
Product Name: 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one Visit Supplier Webpage Request for quotationCAS: 18550-98-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one Visit Supplier Webpage Request for quotationCAS: 18550-98-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History